雄激素受体阻断对前列腺癌PSMA表达影响的临床前评估
该研究在小鼠CRPC模型(C4-2细胞)中评估恩扎卢胺或比卡鲁胺对PSMA表达的调节及联合177Lu-PSMA617的疗效。ARB延迟肿瘤生长并上调PSMA表达,68Ga-PSMA11 PET显示摄取较对照增加至2.3倍。ENZ+RLT组DNA损伤显著增加,但肿瘤生长延迟和生存无显著改善。
要点
- ARB治疗可上调C4-2肿瘤PSMA表达,68Ga-PSMA11 PET显示摄取较对照增加至2.3倍。
- ENZ+RLT组DNA损伤较单药增加,但肿瘤生长延迟和生存无显著改善。
核心结论
- ARB介导的PSMA表达上调可通过68Ga-PSMA11 PET和流式细胞术观察到,177Lu-PSMA617可有效缩小C4-2肿瘤,但ARB预处理未产生协同效应。
研究设计与样本
- 小鼠C4-2 CRPC异种移植模型,分别接受10 mg/kg恩扎卢胺、50 mg/kg比卡鲁胺或对照处理21天,采用68Ga-PSMA11 PET/CT和流式细胞术评估PSMA表达。
- 联合治疗组在10 mg/kg ENZ或对照处理21天后接受15 MBq(84 GBq/μmol)177Lu-PSMA617或对照,以CT肿瘤体积缩小和生存为终点。
主要发现
- ARB延迟肿瘤生长,68Ga-PSMA11摄取随时间较对照增加至2.3倍,流式细胞术证实PSMA表达上调。
- 48小时DNA损伤(phospho-γH2A.X焦点)在ENZ单药和RLT单药增加1.8倍,ENZ+RLT组增加3.4倍。
- ENZ+RLT组较RLT单药组未见额外肿瘤生长延迟(第81天p=0.372),中位生存无显著改善。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). Rational combination therapies may improve treatment efficacy. Here, we explored the effect of androgen receptor blockade (ARB) on PSMA expression visualized by PET and its potential additive effect when combined with 177Lu-PSMA RLT in a mouse model of prostate cancer. METHODS: Mice bearing human CRPC (C4-2 cells) xenografts were treated with 10 mg/kg enzalutamide (ENZ), with 50 mg/kg bicalutamide (BIC), or vehicle (control) for 21 days. PSMA expression was evaluated by 68Ga-PSMA11 PET/CT and quantified by flow cytometry of tumor fine needle aspirations before treatment and on days 23, 29, 34, and 39 post-therapy induction. For the RLT combination approach, mice bearing C4-2 tumors were treated with 10 mg/kg ENZ or vehicle for 21 days before receiving either 15 MBq (84 GBq/μmol) 177Lu-PSMA617 or vehicle. DNA damage was assessed as phospho-γH2A.X foci in tumor biopsies. Reduction of tumor volume on CT and survival were used as study endpoints. RESULTS: Tumor growth was delayed by ARB while 68Ga-PSMA11 uptake increased up to 2.3-fold over time when compared to controls. ABR-induced upregulation of PSMA expression was confirmed by flow cytometry. Phospho-γH2A.X levels increased 1.8- and 3.4-fold at 48 h in response to single treatment ENZ or RLT and ENZ+RLT, respectively. Despite significantly greater DNA damage and persistent increase of PSMA expression at the time of RLT, no additional tumor growth retardation was observed in the ENZ+RLT group (vs. RLT only, p = 0.372 at day 81). Median survival did not improve significantly when ENZ was combined with RLT. CONCLUSION: ARB-mediated increases in PSMA expression in PC xenografts were evident by 68Ga-PSMA11 PET imaging and flow cytometry. 177Lu-PSMA617 effectively decreased C4-2 tumor size. However, while pre-treatment with ARB increased DNA damage significantly, it did not result in synergistic effects when combined with RLT.
引用
- Lückerath K, Wei L, Fendler WP, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018. PMID: 30374743. doi:10.1186/s13550-018-0451-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。